A ranar 16 ga Janairu, 2025, IMPACT ta sanar da cewa Senaparib Capsules (派舒宁®) ta sami izinin tallatawa a China daga Hukumar Kayayyakin Lafiya ta Kasa (NMPA) a matsayin maganin da ake amfani da shi na lokaci guda don kula da marasa lafiya manya da ke fama da cutar epithelial mai tsanani (FIGO Stages III da IV) masu babban matakin ovarian, fallopian tube ko kuma ciwon daji na peritoneal na farko waɗanda ke cikin amsawa (cikakke ko ɓangare) bayan kammala maganin chemotherapy na platinum na farko.
Senaparib, wanda IMPACT ta gano kuma ta haɓaka, wani sabon maganin hana PARP 1/2 ne mai ƙarfi kuma sabon maganin hana PARP 1/2. Tsarin kwayoyin halittarsa na musamman yana ba shi aiki mai yawa a cikin vitro da a cikin jiki, zaɓin manufa na musamman da kuma faffadan taga na aminci. Amincewar ta dogara ne akan Nazarin FLAMES. Binciken wani bincike ne na asibiti na mataki na uku wanda bazuwar, makafi biyu, mai sarrafa placebo, mai cibiya da yawa, don kimanta inganci da amincin Senaparib a matsayin maganin da ba a saba ba don kula da marasa lafiya da ke fama da cutar kansa ta mahaifa waɗanda suka kammala chemotherapy na farko kuma suka sami cikakken amsawa (CR) ko kuma wani ɓangare na amsawa (PR). Sakamakon Nazarin FLAMES ya nuna cewa Senaparib ya nuna babban ci gaba a cikin matsakaicin PFS idan aka kwatanta da placebo (PFS ba ta kai watanni 13.6 ba, HR 0.43, P < 0.0001), ba tare da la'akari da matsayin BRCA ba. Senaparib ya nuna bayanin tsaro mai jurewa, ba tare da wata matsala ta tsaro ba. [1] Sakamakon ya kuma nuna cewa duka HRD masu kyau da HRD marasa kyau sun sami fa'ida daga maganin kulawa na Senaparib, yana nuna yuwuwar Senaparib don amfani da asibiti mai faɗi. Sakamakon wannan binciken zai taimaka wa Senaparib sosai a matsayin Ma'aunin Kulawa don maganin kulawa na farko ga marasa lafiya da aka gano suna da cutar kansar mahaifa.
Sakamakon binciken da aka gabatar a farko an gabatar da shi a matsayin gabatarwa ta baki a ESMO a shekarar 2023 kuma an gabatar da shi a CSCO 2024. A ranar 15 ga Mayu, 2024, mujallar likitanci mai suna Nature Medicine ta buga sakamakon da aka yi wa lakabi da "Senaparib a matsayin maganin kulawa na farko a cikin ciwon daji na mahaifa: gwajin mataki na 3 na bazuwar."
Ciwon daji na ƙwai yana ɗaya daga cikin cututtukan da suka fi kashe mata masu juna biyu. A cewar bayanan GLOBOCAN na 2020, adadin waɗanda suka kamu da cutar kansar ƙwai a duniya ya kai 310,000, kuma mace-macen sun kai 210,000. A cewar sabbin kididdigar cutar kansa ta ƙasa da Cibiyar Kula da Ciwon Daji ta Ƙasa ta fitar a shekarar 2024, an sami sabbin waɗanda suka kamu da cutar kansar ƙwai 61,100 da kuma mace-mace 32,600 a China a shekarar 2022, wanda hakan ya sa ya zama ciwon daji mafi kisa a ƙasar. Saboda alamun farko na cutar kansar ƙwai da ba ta da takamaiman takamaiman magani, kusan kashi 80% na marasa lafiya sun riga sun shiga wani mataki na ci gaba lokacin da aka gano su, kuma adadin waɗanda za su rayu na shekaru 5 shine kashi 41.8% kawai. Duk da cewa cutar kansar ƙwai za a iya magance ta bayan maganin chemotherapy na farko wanda ke ɗauke da platinum, yawancin marasa lafiya ba makawa suna fuskantar sake dawowa, kuma akwai babban buƙatar magani a cikin marasa lafiya da ke fama da cutar kansar ƙwai.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Nassoshi
Lokacin Saƙo: Fabrairu-18-2025